targeting

Natural Nine to Launch Feminine Cleanser in the First Half of Next Year, Targeting Overseas Consumers

HWASEONG, South Korea--(BUSINESS WIRE)--#BodyCareBrand--Natural Nine, a Korean body care brand, announced that it will launch a feminine wash in the…

4 days ago

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Celebrates Indian Independence Day by Honoring the US-India Innovation PartnershipCAMBRIDGE, Mass.--(BUSINESS WIRE)--$HIND--Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company…

3 weeks ago

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in…

1 month ago

Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress

PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of…

1 month ago

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE

Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured…

1 month ago

DP WORLD DELIVERS SAILGP FLEET TO PORT TARGETING NET-ZERO STATUS

DP World, SailGP's Global Smart Logistics Partner, delivers racing fleet into Port of Southampton, ahead of the Emirates Great Britain…

2 months ago

Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing

NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on…

2 months ago

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN…

2 months ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

3 months ago

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial…

3 months ago